Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

<p>12-CK Score from RNA Sequencing</p>

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Roger Li (17078665) (author)
Weitere Verfasser:	Wade J. Sexton (17078668) (author), Jasreman Dhillon (15212961) (author), Anders Berglund (14954401) (author), Shreyas Naidu (17078671) (author), Gustavo Borjas (17078674) (author), Kyle Rose (17078677) (author), Youngchul Kim (9092151) (author), Xuefeng Wang (14955103) (author), Jose R. Conejo-Garcia (14955115) (author), Rohit K. Jain (17078680) (author), Michael A. Poch (17078683) (author), Philippe E. Spiess (17078686) (author), Julio Pow-Sang (17078689) (author), Scott M. Gilbert (17078692) (author), Jingsong Zhang (15037632) (author)
Veröffentlicht:	2025
Schlagworte:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge